Ixazomib Citrate (Systemic)
Brand names: Ninlaro
Drug class:
Antineoplastic Agents
Usage of Ixazomib Citrate (Systemic)
Multiple Myeloma
Used in combination with lenalidomide and dexamethasone for previously treated (≥1 prior therapy) multiple myeloma (designated an orphan drug for this use).
Not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials.
Relate drugs
- Abemaciclib (Systemic)
- Acyclovir (Systemic)
- Adenovirus Vaccine
- Aldomet
- Aluminum Acetate
- Aluminum Chloride (Topical)
- Ambien
- Ambien CR
- Aminosalicylic Acid
- Anacaulase
- Anacaulase
- Anifrolumab (Systemic)
- Antacids
- Anthrax Immune Globulin IV (Human)
- Antihemophilic Factor (Recombinant), Fc fusion protein (Systemic)
- Antihemophilic Factor (recombinant), Fc-VWF-XTEN Fusion Protein
- Antihemophilic Factor (recombinant), PEGylated
- Antithrombin alfa
- Antithrombin alfa
- Antithrombin III
- Antithrombin III
- Antithymocyte Globulin (Equine)
- Antivenin (Latrodectus mactans) (Equine)
- Apremilast (Systemic)
- Aprepitant/Fosaprepitant
- Articaine
- Asenapine
- Atracurium
- Atropine (EENT)
- Avacincaptad Pegol (EENT)
- Avacincaptad Pegol (EENT)
- Axicabtagene (Systemic)
- Clidinium
- Clindamycin (Systemic)
- Clonidine
- Clonidine (Epidural)
- Clonidine (Oral)
- Clonidine injection
- Clonidine transdermal
- Co-trimoxazole
- COVID-19 Vaccine (Janssen) (Systemic)
- COVID-19 Vaccine (Moderna)
- COVID-19 Vaccine (Pfizer-BioNTech)
- Crizanlizumab-tmca (Systemic)
- Cromolyn (EENT)
- Cromolyn (Systemic, Oral Inhalation)
- Crotalidae Polyvalent Immune Fab
- CycloSPORINE (EENT)
- CycloSPORINE (EENT)
- CycloSPORINE (Systemic)
- Cysteamine Bitartrate
- Cysteamine Hydrochloride
- Cysteamine Hydrochloride
- Cytomegalovirus Immune Globulin IV
- A1-Proteinase Inhibitor
- A1-Proteinase Inhibitor
- Bacitracin (EENT)
- Baloxavir
- Baloxavir
- Bazedoxifene
- Beclomethasone (EENT)
- Beclomethasone (Systemic, Oral Inhalation)
- Belladonna
- Belsomra
- Benralizumab (Systemic)
- Benzocaine (EENT)
- Bepotastine
- Betamethasone (Systemic)
- Betaxolol (EENT)
- Betaxolol (Systemic)
- Bexarotene (Systemic)
- Bismuth Salts
- Botulism Antitoxin (Equine)
- Brimonidine (EENT)
- Brivaracetam
- Brivaracetam
- Brolucizumab
- Brompheniramine
- Budesonide (EENT)
- Budesonide (Systemic, Oral Inhalation)
- Bulk-Forming Laxatives
- Bupivacaine (Local)
- BuPROPion (Systemic)
- Buspar
- Buspar Dividose
- Buspirone
- Butoconazole
- Cabotegravir (Systemic)
- Caffeine/Caffeine and Sodium Benzoate
- Calcitonin
- Calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate
- Calcium Salts
- Calcium, magnesium, potassium, and sodium oxybates
- Candida Albicans Skin Test Antigen
- Cantharidin (Topical)
- Capmatinib (Systemic)
- Carbachol
- Carbamide Peroxide
- Carbamide Peroxide
- Carmustine
- Castor Oil
- Catapres
- Catapres-TTS
- Catapres-TTS-1
- Catapres-TTS-2
- Catapres-TTS-3
- Ceftolozane/Tazobactam (Systemic)
- Cefuroxime
- Centruroides Immune F(ab′)2
- Cetirizine (EENT)
- Charcoal, Activated
- Chloramphenicol
- Chlorhexidine (EENT)
- Chlorhexidine (EENT)
- Cholera Vaccine Live Oral
- Choriogonadotropin Alfa
- Ciclesonide (EENT)
- Ciclesonide (Systemic, Oral Inhalation)
- Ciprofloxacin (EENT)
- Citrates
- Dacomitinib (Systemic)
- Dapsone (Systemic)
- Dapsone (Systemic)
- Daridorexant
- Darolutamide (Systemic)
- Dasatinib (Systemic)
- DAUNOrubicin and Cytarabine
- Dayvigo
- Dehydrated Alcohol
- Delafloxacin
- Delandistrogene Moxeparvovec (Systemic)
- Dengue Vaccine Live
- Dexamethasone (EENT)
- Dexamethasone (Systemic)
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine (Intravenous)
- Dexmedetomidine (Oromucosal)
- Dexmedetomidine buccal/sublingual
- Dexmedetomidine injection
- Dextran 40
- Diclofenac (Systemic)
- Dihydroergotamine
- Dimethyl Fumarate (Systemic)
- Diphenoxylate
- Diphtheria and Tetanus Toxoids
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Diroximel Fumarate (Systemic)
- Docusate Salts
- Donislecel-jujn (Systemic)
- Doravirine, Lamivudine, and Tenofovir Disoproxil
- Doxepin (Systemic)
- Doxercalciferol
- Doxycycline (EENT)
- Doxycycline (Systemic)
- Doxycycline (Systemic)
- Doxylamine
- Duraclon
- Duraclon injection
- Dyclonine
- Edaravone
- Edluar
- Efgartigimod Alfa (Systemic)
- Eflornithine
- Eflornithine
- Elexacaftor, Tezacaftor, And Ivacaftor
- Elranatamab (Systemic)
- Elvitegravir, Cobicistat, Emtricitabine, and tenofovir Disoproxil Fumarate
- Emicizumab-kxwh (Systemic)
- Emtricitabine and Tenofovir Disoproxil Fumarate
- Entrectinib (Systemic)
- EPINEPHrine (EENT)
- EPINEPHrine (Systemic)
- Erythromycin (EENT)
- Erythromycin (Systemic)
- Estrogen-Progestin Combinations
- Estrogen-Progestin Combinations
- Estrogens, Conjugated
- Estropipate; Estrogens, Esterified
- Eszopiclone
- Ethchlorvynol
- Etranacogene Dezaparvovec
- Evinacumab (Systemic)
- Evinacumab (Systemic)
- Factor IX (Human), Factor IX Complex (Human)
- Factor IX (Recombinant)
- Factor IX (Recombinant), albumin fusion protein
- Factor IX (Recombinant), Fc fusion protein
- Factor VIIa (Recombinant)
- Factor Xa (recombinant), Inactivated-zhzo
- Factor Xa (recombinant), Inactivated-zhzo
- Factor XIII A-Subunit (Recombinant)
- Faricimab
- Fecal microbiota, live
- Fedratinib (Systemic)
- Fenofibric Acid/Fenofibrate
- Fibrinogen (Human)
- Flunisolide (EENT)
- Fluocinolone (EENT)
- Fluorides
- Fluorouracil (Systemic)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Fluticasone (EENT)
- Fluticasone (Systemic, Oral Inhalation)
- Fluticasone and Vilanterol (Oral Inhalation)
- Ganciclovir Sodium
- Gatifloxacin (EENT)
- Gentamicin (EENT)
- Gentamicin (Systemic)
- Gilteritinib (Systemic)
- Glofitamab
- Glycopyrronium
- Glycopyrronium
- Gonadotropin, Chorionic
- Goserelin
- Guanabenz
- Guanadrel
- Guanethidine
- Guanfacine
- Haemophilus b Vaccine
- Hepatitis A Virus Vaccine Inactivated
- Hepatitis B Vaccine Recombinant
- Hetlioz
- Hetlioz LQ
- Homatropine
- Hydrocortisone (EENT)
- Hydrocortisone (Systemic)
- Hydroquinone
- Hylorel
- Hyperosmotic Laxatives
- Ibandronate
- Igalmi buccal/sublingual
- Imipenem, Cilastatin Sodium, and Relebactam
- Inclisiran (Systemic)
- Infliximab, Infliximab-dyyb
- Influenza Vaccine Live Intranasal
- Influenza Vaccine Recombinant
- Influenza Virus Vaccine Inactivated
- Inotuzumab
- Insulin Human
- Interferon Alfa
- Interferon Beta
- Interferon Gamma
- Intermezzo
- Intuniv
- Iodoquinol (Topical)
- Iodoquinol (Topical)
- Ipratropium (EENT)
- Ipratropium (EENT)
- Ipratropium (Systemic, Oral Inhalation)
- Ismelin
- Isoproterenol
- Ivermectin (Systemic)
- Ivermectin (Topical)
- Ixazomib Citrate (Systemic)
- Japanese Encephalitis Vaccine
- Kapvay
- Ketoconazole (Systemic)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (Systemic)
- Ketotifen
- Lanthanum
- Lecanemab
- Lefamulin
- Lemborexant
- Lenacapavir (Systemic)
- Leniolisib
- Letermovir
- Letermovir
- Levodopa/Carbidopa
- LevoFLOXacin (EENT)
- LevoFLOXacin (Systemic)
- L-Glutamine
- Lidocaine (Local)
- Lidocaine (Systemic)
- Linezolid
- Lofexidine
- Loncastuximab
- Lotilaner (EENT)
- Lotilaner (EENT)
- Lucemyra
- Lumasiran Sodium
- Lumryz
- Lunesta
- Mannitol
- Mannitol
- Mb-Tab
- Measles, Mumps, and Rubella Vaccine
- Mecamylamine
- Mechlorethamine
- Mechlorethamine
- Melphalan (Systemic)
- Meningococcal Groups A, C, Y, and W-135 Vaccine
- Meprobamate
- Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
- Methyldopa
- Methylergonovine, Ergonovine
- MetroNIDAZOLE (Systemic)
- MetroNIDAZOLE (Systemic)
- Miltown
- Minipress
- Minocycline (EENT)
- Minocycline (Systemic)
- Minoxidil (Systemic)
- Mometasone
- Mometasone (EENT)
- Moxifloxacin (EENT)
- Moxifloxacin (Systemic)
- Nalmefene
- Naloxone (Systemic)
- Natrol Melatonin + 5-HTP
- Nebivolol Hydrochloride
- Neomycin (EENT)
- Neomycin (Systemic)
- Netarsudil Mesylate
- Nexiclon XR
- Nicotine
- Nicotine
- Nicotine
- Nilotinib (Systemic)
- Nirmatrelvir
- Nirmatrelvir
- Nitroglycerin (Systemic)
- Ofloxacin (EENT)
- Ofloxacin (Systemic)
- Oliceridine Fumarate
- Olipudase Alfa-rpcp (Systemic)
- Olopatadine
- Omadacycline (Systemic)
- Osimertinib (Systemic)
- Oxacillin
- Oxymetazoline
- Pacritinib (Systemic)
- Palovarotene (Systemic)
- Paraldehyde
- Peginterferon Alfa
- Peginterferon Beta-1a (Systemic)
- Penicillin G
- Pentobarbital
- Pentosan
- Pilocarpine Hydrochloride
- Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate
- Placidyl
- Plasma Protein Fraction
- Plasminogen, Human-tmvh
- Pneumococcal Vaccine
- Polymyxin B (EENT)
- Polymyxin B (Systemic, Topical)
- PONATinib (Systemic)
- Poractant Alfa
- Posaconazole
- Potassium Supplements
- Pozelimab (Systemic)
- Pramoxine
- Prazosin
- Precedex
- Precedex injection
- PrednisoLONE (EENT)
- PrednisoLONE (Systemic)
- Progestins
- Propylhexedrine
- Protamine
- Protein C Concentrate
- Protein C Concentrate
- Prothrombin Complex Concentrate
- Pyrethrins with Piperonyl Butoxide
- Quviviq
- Ramelteon
- Relugolix, Estradiol, and Norethindrone Acetate
- Remdesivir (Systemic)
- Respiratory Syncytial Virus Vaccine, Adjuvanted (Systemic)
- RifAXIMin (Systemic)
- Roflumilast (Systemic)
- Roflumilast (Topical)
- Roflumilast (Topical)
- Rotavirus Vaccine Live Oral
- Rozanolixizumab (Systemic)
- Rozerem
- Ruxolitinib (Systemic)
- Saline Laxatives
- Selenious Acid
- Selexipag
- Selexipag
- Selpercatinib (Systemic)
- Sirolimus (Systemic)
- Sirolimus, albumin-bound
- Smallpox and Mpox Vaccine Live
- Smallpox Vaccine Live
- Sodium Chloride
- Sodium Ferric Gluconate
- Sodium Nitrite
- Sodium oxybate
- Sodium Phenylacetate and Sodium Benzoate
- Sodium Thiosulfate (Antidote) (Systemic)
- Sodium Thiosulfate (Protectant) (Systemic)
- Somatrogon (Systemic)
- Sonata
- Sotorasib (Systemic)
- Suvorexant
- Tacrolimus (Systemic)
- Tafenoquine (Arakoda)
- Tafenoquine (Krintafel)
- Talquetamab (Systemic)
- Tasimelteon
- Tedizolid
- Telotristat
- Tenex
- Terbinafine (Systemic)
- Tetrahydrozoline
- Tezacaftor and Ivacaftor
- Theophyllines
- Thrombin
- Thrombin Alfa (Recombinant) (Topical)
- Timolol (EENT)
- Timolol (Systemic)
- Tixagevimab and Cilgavimab
- Tobramycin (EENT)
- Tobramycin (Systemic)
- TraMADol (Systemic)
- Trametinib Dimethyl Sulfoxide
- Trancot
- Tremelimumab
- Tretinoin (Systemic)
- Triamcinolone (EENT)
- Triamcinolone (Systemic)
- Trimethobenzamide
- Tucatinib (Systemic)
- Unisom
- Vaccinia Immune Globulin IV
- Valoctocogene Roxaparvovec
- Valproate/Divalproex
- Valproate/Divalproex
- Vanspar
- Varenicline (Systemic)
- Varenicline (Systemic)
- Varenicline Tartrate (EENT)
- Vecamyl
- Vitamin B12
- Vonoprazan, Clarithromycin, and Amoxicillin
- Wytensin
- Xyrem
- Xywav
- Zaleplon
- Zirconium Cyclosilicate
- Zolpidem
- Zolpidem (Oral)
- Zolpidem (Oromucosal, Sublingual)
- ZolpiMist
- Zoster Vaccine Recombinant
- 5-hydroxytryptophan, melatonin, and pyridoxine
How to use Ixazomib Citrate (Systemic)
General
Pretreatment Screening
Patient Monitoring
Premedication and Prophylaxis
Dispensing and Administration Precautions
Other General Considerations
Administration
Oral Administration
Administer orally once weekly on the same day and at approximately the same time for the first 3 weeks of each 4-week cycle.
Administer orally at least 1 hour before or at least 2 hours after food.
Do not administer ixazomib and dexamethasone simultaneously on days when both drugs are scheduled; administer dexamethasone with food and give ixazomib on an empty stomach.
Swallow capsules whole with water; do not crush, chew, or open.
If vomiting occurs following administration, do not repeat the dose. Resume therapy at time of next scheduled dose.
If a dose is delayed or missed, administer the dose only if there are at least 72 hours until the next scheduled dose. Do not administer a missed dose within 72 hours of the next scheduled dose; do not double the dose to make up for the missed dose.
Instruct patients to take ixazomib exactly as prescribed. Discuss all dosage instructions with the patient prior to initiation of therapy. Overdosage of ixazomib has resulted in fatality.
Dosage
Available as ixazomib citrate; dosage expressed in terms of ixazomib.
Adults
Multiple Myeloma OralRecommended initial dosage in each 28-day cycle: Ixazomib 4 mg once weekly on days 1, 8, and 15 in combination with lenalidomide 25 mg once daily on days 1–21 and dexamethasone 40 mg on days 1, 8, 15, and 22.
Continue treatment until disease progression or unacceptable toxicity occurs.
Consult manufacturer's labeling for lenalidomide and dexamethasone for additional information.
Dosage Modification for Toxicity OralAdverse effects may require temporary interruption, dosage reduction, and/or permanent discontinuance. Up to 2 dosage reductions for toxicity is recommended.
If dosage reduction from the recommended dosage of 4 mg once weekly is necessary, initially reduce dosage to 3 mg once weekly. If further dosage reduction is necessary, reduce dosage to 2.3 mg once weekly. Dosages <2.3 mg once weekly not recommended.
Neutropenia OralIf ANC <500/mm3, withhold ixazomib and lenalidomide until ANC is ≥500/mm3. Consider addition of granulocyte colony-stimulating factors (G-CSF) based on clinical guidelines.
When ANC returns to ≥500/mm3, reduce lenalidomide by 1 dose level according to manufacturer's labeling; resume ixazomib at previous dosage. If ANC <500/mm3 recurs, withhold ixazomib and lenalidomide until ANC ≥500/mm3; reduce ixazomib by 1 dose level (i.e., a dose of 4 mg reduced to 3 mg or a dose of 3 mg reduced to 2.3 mg); resume lenalidomide at previous dosage.
For additional occurrences of neutropenia, alternate dosage modifications between ixazomib and lenalidomide. Following a second dosage reduction of ixazomib, discontinue treatment if ANC <500/mm3 recurs.
Thrombocytopenia OralIf platelet count <30,000/mm3, withhold ixazomib and lenalidomide until platelet count is ≥30,000/mm3.
When platelet count returns to ≥30,000/mm3, resume ixazomib at previous dosage; resume lenalidomide at 1 dose level lower than the previous dosage according to manufacturer's labeling. If platelet count <30,000/mm3 recurs, withhold ixazomib and lenalidomide until platelet count is ≥30,000/mm3; resume ixazomib at 1 dose level lower than the previous dose (i.e., a dose of 4 mg reduced to 3 mg or a dose of 3 mg reduced to 2.3 mg); resume lenalidomide at previous dose.
For additional occurrences of thrombocytopenia, alternate dosage modifications between ixazomib and lenalidomide. Following a second dosage reduction of ixazomib, discontinue treatment if platelet count <30,000/mm3 recurs.
Peripheral Neuropathy OralIf grade 1 peripheral neuropathy with pain or grade 2 peripheral neuropathy occurs, withhold ixazomib until toxicity resolves to grade 1 or less without pain or to baseline; resume ixazomib at the previous dosage. Discontinue treatment if grade 1 peripheral neuropathy with pain or grade 2 peripheral neuropathy occurs following a second dosage reduction of ixazomib.
If grade 2 peripheral neuropathy with pain or grade 3 peripheral neuropathy occurs, withhold ixazomib; generally (at clinician's discretion) allow toxicity to resolve to baseline or grade 1 or less prior to resuming therapy. Resume ixazomib at 1 dose level lower than the previous dosage (i.e., a dose of 4 mg reduced to 3 mg or a dose of 3 mg reduced to 2.3 mg).
Discontinue treatment if grade 2 peripheral neuropathy with pain or grade 3 peripheral neuropathy occurs following a second dosage reduction of ixazomib.
If any grade 4 peripheral neuropathy occurs, discontinue treatment.
Dermatologic Toxicity OralIf grade 2 or 3 rash occurs, withhold lenalidomide until rash resolves to grade 1 or less; resume lenalidomide at 1 dose level lower than the previous dosage according to manufacturer's labeling.
If grade 2 or 3 rash recurs, withhold ixazomib and lenalidomide until rash resolves to grade 1 or less; resume ixazomib at 1 dose level lower than the previous dosage (i.e., a dose of 4 mg reduced to 3 mg or a dose of 3 mg reduced to 2.3 mg); resume lenalidomide at the previous dosage.
For additional occurrences of rash, alternate dosage modifications between ixazomib and lenalidomide. Discontinue treatment if grade 2 or 3 rash occurs following a second dosage reduction of ixazomib.
Discontinue treatment if any grade 4 rash occurs.
Other Nonhematologic Toxicity OralIf other grade 3 or 4 nonhematologic toxicity occurs, withhold ixazomib; generally (at clinician's discretion) allow toxicity to resolve to baseline or grade 1 or less. If nonhematologic toxicity is attributable to ixazomib, resume therapy at 1 dose level lower than the previous dosage (i.e., a dose of 4 mg reduced to 3 mg or a dose of 3 mg reduced to 2.3 mg).
Discontinue treatment if grade 3 or 4 nonhematologic toxicity occurs following a second dosage reduction of ixazomib.
Special Populations
Hepatic Impairment
Reduce initial dosage of ixazomib to 3 mg weekly in patients with moderate (total bilirubin >1.5 to 3 times the ULN) or severe (total bilirubin >3 times the ULN) hepatic impairment. Refer to manufacturer's labeling for lenalidomide for specific dosage recommendations.
Renal Impairment
Reduce initial dosage of ixazomib to 3 mg weekly in patients with severe renal impairment (Clcr <30 mL/minute) or in patients with end-stage renal disease (ESRD) requiring dialysis. Ixazomib is not dialyzable; administer without regard to timing of dialysis. Refer to manufacturer's labeling for lenalidomide for specific dosage recommendations.
Geriatric Patients
Manufacturer makes no special dosage recommendations.
Warnings
Contraindications
Warnings/Precautions
Thrombocytopenia
Thrombocytopenia reported frequently. Platelet nadirs usually occur on days 14–21 of each 28-day cycle and resolve to baseline by beginning of next cycle.
Monitor platelet counts at least monthly. Consider more frequent monitoring during the first 3 treatment cycles. Manage thrombocytopenia with dosage modifications and platelet transfusions according to standard of care.
GI Toxicity
GI toxicity reported (e.g., diarrhea, constipation, nausea, vomiting), requiring occasional use of antidiarrheal or antiemetic drugs and/or supportive care. Modify dosage in patients experiencing grade 3 or 4 GI toxicity.
Peripheral Neuropathy
Peripheral neuropathy (usually sensory neuropathy and mostly grade 1 or 2) reported.
Monitor patients for symptoms of peripheral neuropathy; dosage modifications may be required in those experiencing new or worsening symptoms.
Peripheral Edema
Peripheral edema (mostly grade 1 or 2) reported. Assess for underlying causes and provide supportive care, as needed. Adjust dosage of ixazomib for grade 3 or 4 symptoms, and modify dosing of dexamethasone based on manufacturer's labeling.
Dermatologic Reactions
Rash (mostly grade 1 or 2) reported. Maculopapular and macular rash reported most frequently. Manage with supportive care or with dosage modification if grade 2 or greater.
Thrombotic Microangiopathy
Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura/hemolytic uremic syndrome), sometimes fatal, reported.
Monitor for signs and symptoms. If manifestations suggestive of these conditions occur, temporarily interrupt ixazomib therapy and exclude possibility of other etiologies. If the diagnosis of thrombotic thrombocytopenic purpura or hemolytic uremic syndrome is excluded, consider restarting ixazomib; safety of reinitiating ixazomib therapy in such patients is unknown.
Hepatotoxicity
Hepatotoxicity reported (e.g., drug-induced hepatic injury, hepatocellular injury, hepatic steatosis, cholestatic hepatitis, hepatotoxicity). Monitor hepatic enzymes regularly; adjust dosage in patients experiencing grade 3 or 4 toxicity.
Fetal/Neonatal Morbidity and Mortality
May cause fetal harm. Embryofetal toxicity demonstrated in animals.
Avoid pregnancy during therapy. Verify pregnancy status in females of reproductive potential prior to initiating therapy. If used during pregnancy, or patient becomes pregnant, apprise of potential fetal hazard. Females of reproductive potential and males who are partners of such females must use effective nonhormonal contraceptive methods during treatment and for 90 days following discontinuance of the drug. Because ixazomib is administered with dexamethasone, and dexamethasone can potentially interact and reduce concentrations of hormonal contraceptives, consider the possibility of reduced contraceptive efficacy.
Increased Mortality in Patients Treated with Ixazomib in the Maintenance Setting
Increased deaths reported in multiple myeloma patients receiving maintenance treatment with ixazomib. Treatment in the maintenance setting not recommended outside of controlled trials.
Specific Populations
PregnancyMay cause fetal harm.
Verify pregnancy status in females of reproductive potential prior to initiating therapy.
LactationNot known whether ixazomib or its metabolites are distributed into human milk or affect milk production or breast-fed infants. Breast-feeding is not recommended during therapy and for 90 days after the last dose.
Pediatric UseSafety and efficacy not established.
Geriatric UseIn clinical trials, 55% of patients were ≥65 years of age; 17% were ≥75 years of age. No overall differences in safety or efficacy observed between geriatric patients and younger adults; other clinical experience has not demonstrated differences in responses between geriatric and younger patients. However, greater sensitivity of some older patients cannot be ruled out.
Hepatic ImpairmentPharmacokinetics similar in patients with normal hepatic function and in those with mild hepatic impairment (total bilirubin less than or equal to the ULN and AST concentrations greater than the ULN, or total bilirubin >1 to 1.5 times the ULN with any AST concentration). Mean AUC increased substantially in those with moderate or severe hepatic impairment compared with patients with normal hepatic function.
Reduce initial dosage in patients with moderate or severe hepatic impairment.
Renal ImpairmentPharmacokinetics similar in patients with normal renal function and in those with mild (Clcr 60–89 mL/minute) or moderate (Clcr 30–59 mL/minute) renal impairment. Mean AUC increased substantially in patients with severe renal impairment or ESRD requiring dialysis compared with those with normal renal function.
Reduce initial dosage in patients with severe renal impairment or ESRD requiring dialysis.
Common Adverse Effects
Adverse effects (≥20%): thrombocytopenia, neutropenia, rash, bronchitis, vomiting, peripheral edema, nausea, peripheral neuropathy, constipation, diarrhea.
What other drugs will affect Ixazomib Citrate (Systemic)
Low-affinity substrate of P-glycoprotein (P-gp); not a substrate of breast cancer resistance protein (BCRP), multidrug resistance protein (MRP) 2, or hepatic organic anion transport protein (OATP).
Not a reversible or time-dependent inhibitor of CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5. Not expected to cause interactions via CYP inhibition.
Not an inhibitor of P-gp, BCRP, MRP2, OATP 1B1 or 1B3, organic cation transporter (OCT) 2, organic anion transporter (OAT) 1 or 3, or multidrug and toxin extrusion (MATE) 1 or MATE2K transporters. Not expected to cause transporter-mediated pharmacokinetic interactions.
Not an inducer of CYP1A2, 2B6, or 3A4/5 or corresponding immunoreactive protein concentrations. Not expected to cause interactions via CYP induction.
Drugs Affecting Hepatic Microsomal Enzymes
Potent CYP1A2 inhibitors: No clinically important change in the systemic exposure of ixazomib.
Potent CYP3A inducers: Possible decreased systemic exposure of ixazomib. Avoid concomitant use.
Specific Drugs
Drug
Interaction
Comments
Possible decreased systemic exposure of ixazomib
Avoid concomitant use
Clarithromycin
No clinically important effect on systemic exposure of ixazomib
Phenytoin
Possible decreased systemic exposure of ixazomib
Avoid concomitant use
Rifampin
Decreased peak plasma concentration and AUC of ixazomib
Avoid concomitant use
St. John's wort (Hypericum perforatum)
Possible decreased systemic exposure of ixazomib
Avoid concomitant use
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions